Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card!
Anders Åberg has been the CEO of Sprint Bioscience AB (publ) (STO:SPRINT) since 2009. This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similar size. After that, we will consider the growth in the business. And finally we will reflect on how common stockholders have fared in the last few years, as a secondary measure of performance. The aim of all this is to consider the appropriateness of CEO pay levels.
How Does Anders Åberg's Compensation Compare With Similar Sized Companies?
According to our data, Sprint Bioscience AB (publ) has a market capitalization of kr191m, and pays its CEO total annual compensation worth kr1.3m. (This is based on the year to December 2018). We think total compensation is more important but we note that the CEO salary is lower, at kr1.1m. We looked at a group of companies with market capitalizations under kr1.9b, and the median CEO total compensation was kr1.1m.
So Anders Åberg is paid around the average of the companies we looked at. While this data point isn't particularly informative alone, it gains more meaning when considered with business performance.
You can see, below, how CEO compensation at Sprint Bioscience has changed over time.
Is Sprint Bioscience AB (publ) Growing?
Sprint Bioscience AB (publ) has reduced its earnings per share by an average of 61% a year, over the last three years (measured with a line of best fit). Its revenue is down -69% over last year.
Few shareholders would be pleased to read that earnings per share are lower over three years. And the impression is worse when you consider revenue is down year-on-year. These factors suggest that the business performance wouldn't really justify a high pay packet for the CEO. We don't have analyst forecasts, but you might want to assess this data-rich visualization of earnings, revenue and cash flow.
Has Sprint Bioscience AB (publ) Been A Good Investment?
With a three year total loss of 58%, Sprint Bioscience AB (publ) would certainly have some dissatisfied shareholders. So shareholders would probably think the company shouldn't be too generous with CEO compensation.
Anders Åberg is paid around what is normal the leaders of comparable size companies.
The company isn't growing EPS, and shareholder returns have been disappointing. Few would argue that it's wise for the company to pay any more, before returns improve. Shareholders may want to check for free if Sprint Bioscience insiders are buying or selling shares.
Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.
We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
If you spot an error that warrants correction, please contact the editor at email@example.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.